Endocrine Today has compiled a list of the top five news reports from the American Diabetes Association Scientific Session in June.
Healio.com/Endocrinology readers were interested in amputation risk with SGLT2 inhibitors, type 2 diabetes prognosis in teens, real-world accuracy of CGMs and more.
OBSERVE-4D: No amputation risk with canagliflozin in type 2 diabetes
Adults with type 2 diabetes with and without established cardiovascular disease treated with the SGLT2 inhibitor canagliflozin did not have an increased risk for below-the-knee amputation compared with patients assigned similar SGLT2 inhibitors or other antidiabetes therapies, according to findings from the OBSERVE-4D study. Read more.
RISE: Type 2 diabetes more aggressive in adolescents; early treatment unlikely to slow progression
Adolescents with prediabetes or newly diagnosed type 2 diabetes have much more aggressive disease than adults with similar glycemic profiles, and early treatment with insulin and metformin does not substantially slow its progression, according to data from three RISE studies. Read more.
Head-to-head comparison shows real-world accuracy differences among CGM devices
Among adults with type 1 diabetes concurrently wearing three continuous glucose monitoring devices, accuracy of the devices was lower than reported in clinical studies. Read more.
Metreleptin aids in weight reduction among adults with obesity plus very low leptin levels
Adults with obesity and low endogenous levels of leptin lost more weight after treatment with the leptin analogue metreleptin than with placebo, and lower leptin levels were associated with greater weight loss. Read more.
Insights from TEDDY study provide clues to islet autoimmunity in children
Data from the ongoing TEDDY study show that there are two diabetes-related endotypes defined by insulin autoantibodies or glutamic acid decarboxylase autoantibodies as the first appearing autoantibody in children, and ongoing research suggests several maternal, childhood and familial factors play a role in islet autoimmunity risk. Read more.